The FDA has evaluated BPC-157 as a bulk drug substance for compounding and raised questions about its safety data
Because FOXO4-DRIs mechanism depends on disrupting the FOXO4p53 interaction, and because this interaction is only operative in cells with elevated FOXO4 expression, the compound preferentially targets the senescent cell population leaving FOXO4-low non-senescent cells largely unaffected
We can help you make this informed decision after six months
A direct head-to-head trial is underway (with initial results due later in 2026), and current data shows that when the highest dose of each drug is taken over a 72-week period, those on tirzepatide returned a higher percentage of total body weight loss (20.2% - 21.1% as opposed to 13.7% - 14.1% for semaglutide (as detailed in the New England Journal of Medicine Study of May 2025)
But going straight to injectable glutathione while ignoring NAC optimization is like skipping over the blueprint to build a house and then wondering why the house doesnt stand on its own legs
No membership fees apply, and you can discontinue at any time